<?xml version="1.0" encoding="UTF-8"?>
<p>Thirty-four patients with a confirmed diagnosis of hemoglobinopathy and HCV infection were treated with DAAs in the period 2015–2018. The characteristics of the patients are described in 
 <xref rid="T1" ref-type="table">Table 1</xref>. In particular, 28 subjects (16 females and 12 males, mean age 44 ± 7 years) affected by Thalassemia Major, 3 subjects (2 females and 1 males) affected by Thalassemia Intermedia, and 3 subjects (1 female and 2 males) with Sickle Cell Disease (two with HbS/β Thalassemia and one with HbS/HbS). All subjects were transfusion dependent, and because of the iron overload an iron chelation therapy was administered: deferoxamine (DFO) in 29% of patients, deferiprone (DFP) in 13% of patients, deferasirox (DFX) in 25% of patients, DFO + DFP in 23% of patients, and DFO + DFX in 10% of patients. The iron chelation therapies were different and personalized for the patients, the dosages of iron chelators are reported in 
 <xref rid="T1" ref-type="table">Table 1</xref>.
</p>
